RichardJWhitleyMD
Pediatric Infectious Disease • Birmingham, ALProfessor, Pediatrics, University of Alabama School of Medicine
Dr. Whitley is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1600 6th Ave S
Ste 303
Birmingham, AL 35233Phone+1 205-638-9181
Summary
- Distinguished Professor of Pediatrics
Education & Training
University of Alabama Medical CenterResidency, Pediatrics, 1971 - 1975
George Washington University School of Medicine and Health SciencesClass of 1971
Certifications & Licensure
AL State Medical License 1973 - 2024- American Board of Pediatrics Pediatrics
Awards, Honors, & Recognition
- Elected Member The American Society for Clinical Investigation, 1989
- Fellow (FAAP) American Academy of Pediatrics
Clinical Trials
- Phase I/II Study of Human Anti-Cytomegalovirus (CMV) Monoclonal Antibody MSL-109 in Newborns With Symptomatic Congenital CMV Infection Without Central Nervous System Disease Start of enrollment: 1995 Feb 01
- Phase I/II Study of High-Dose Acyclovir for Central Nervous System or Disseminated Neonatal Herpes Simplex Virus Infection Start of enrollment: 1995 Feb 01
- Phase III Randomized, Placebo-Controlled Study of Acyclovir Oral Suspension for Neonatal Herpes Simplex Virus Infection Limited to the Skin, Eyes, and Mouth Start of enrollment: 1992 Aug 01
- Join now to see all
Publications & Presentations
PubMed
- 199 citationsTherapeutic strategies for COVID-19: progress and lessons learned.Guangdi Li, Rolf Hilgenfeld, Richard Whitley, Erik De Clercq
Nature Reviews. Drug Discovery. 2023-06-01 - 783 citationsHerpes simplex virus infectionsRichard J. Whitley, Bernard Roizman
Lancet. 2001-05-12 - 35 citationsThe development of new therapies for human herpesvirus 6Mark N. Prichard, Richard J. Whitley
Current Opinion in Virology. 2014-12-01
Press Mentions
- Altesa BioSciences Announces Scientific Advisory BoardFebruary 28th, 2022
- Merck's COVID Pill Shows 'Modest' Benefit in High-Risk OutpatientsDecember 16th, 2021
- There Are Few Good COVID Antivirals, but That Could Be ChangingJuly 15th, 2021
- Join now to see all
Grant Support
- Preclinical Evaluation Of Oncolytic HSV For Anaplastic Glioma TherapyNational Cancer Institute2009–2011
- Engineered HSV For Treatment Of Malignant GliomaNational Cancer Institute2009–2011
- Administrative CoreNational Cancer Institute2009–2011
- Development Of Antiviral Screens And Animal ModelsNational Institute Of Allergy And Infectious Diseases2008
- Engineered HSV For Treatment Of Malignant GliomasNational Cancer Institute2003–2007
- High Dose Acyclovir Versus Vidarabine In Neonatal Herpes Simplex InfectionNational Center For Research Resources1998–2002
- Ganciclovir (DHPG) For Symptomatic Congenital Cytomegalovirus InfectionsNational Center For Research Resources1997–2002
- Engineered Herpes Simplex Virus For Treatment Of GliomasNational Cancer Institute1997–2001
- Biologic Characterization Of Engineered HSV For Therapy Of Brain TumorsNational Cancer Institute1997–2001
- PDL MSL 109 In Infants With NON CNS Symptomatic Congenital CMV InfectionsNational Center For Research Resources1998–2000
- Clinical Studies Of Therapies For Virus InfectionsNational Institute Of Allergy And Infectious Diseases1996–2000
- Recurrent Skin Vesicles Following Neonatal HSV Of The Skin, Eye &MouthNational Center For Research Resources1998–1999
- Core--ClinicalNational Institute Of Allergy And Infectious Diseases1997
- High Dose Ganciclovir(Dhpg) For Symptomatic Congenital Cytomegalovirus InfectionNational Center For Research Resources1997
- In Vivo Animal Model Evaluation Of Candidate VaccinesNational Institute Of Allergy And Infectious Diseases1992–1995
- Sixth International Conference On Antiviral ResearchNational Institute Of Allergy And Infectious Diseases1993
- Fifth International Conference On Antiviral ResearchNational Institute Of Allergy And Infectious Diseases1992
- Fourth International Conference On Antiviral ResearchNational Institute Of Allergy And Infectious Diseases1991
- Birmingham NcddgNational Institute Of Allergy And Infectious Diseases1987–1991
- Third International Conference On Antiviral ResearchNational Institute Of Allergy And Infectious Diseases1990
- Trial On Antivirals For Severe Herpes Virus InfectionsNational Institute Of Allergy And Infectious Diseases1986–1990
- Trial On Antivirals For Severe Herpesvirus InfectionsNational Institute Of Allergy And Infectious Diseases1986
- Efficacy Trials Of Antivirals For Severe Herpes VirusNational Institute Of Allergy And Infectious Diseases1985–1986
Professional Memberships
- Fellow
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
